The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeted agents for the treatment of hormone receptor–-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+/HER2- MBC) with co-alterations in ESR1 and AKT pathway: A retrospective analysis.
 
Naomi Dempsey
Honoraria - Curio Science; Elsevier; Lilly; Novartis; OncLive/MJH Life Sciences; Precisca
Consulting or Advisory Role - Ashfield Healthcare; Gilead Sciences; Lilly; NeoGenomics Laboratories; Novartis; Pfizer
Speakers' Bureau - Seagen
Travel, Accommodations, Expenses - Gilead Sciences; Precisca
 
Yolcar Chamorro
No Relationships to Disclose
 
Priya Bhatt
Honoraria - OncLive/MJH Life Sciences; Total Health Conferencing
 
Natasha Harpalani
No Relationships to Disclose
 
Lydia Hodgson
No Relationships to Disclose
 
Ana Sandoval-Leon
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Guardant Health; Merck; Oncocyte; Sanofi/Aventis; Sermonix Pharmaceuticals; Stemline Therapeutics
Research Funding - AstraZeneca (Inst); OBI Pharma (Inst); Seagen (Inst)
 
Lauren Carcas
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca
 
Reagan Barnett
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Cara Elmstrom
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Manmeet Ahluwalia
Stock and Other Ownership Interests - doctible; MedInnovate Advisors LLC; MimiVax; TriSalus Life Sciences
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - AlloVir; Anheart Therapeutics; Apollomics; Autem Therapeutics; Bayer; Bugworks; Cairn Therapeutics; Caris Life Sciences; Equillium; GlaxoSmithKline; InSightec; Janssen; Menarini Group; Modifi Bio; NH TherAguix; Nuvation Bio; Prelude Therapeutics; Pyramid Biosciences; SDP Oncology; Siemens Healhineers/Varian Medical Systems; Sumitomo Dainippon Pharma Oncology; ViewRay; Voyager Therapeutics; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst); Seagen (Inst)
Other Relationship - Idorsia (I); ResMed (I)
 
Reshma Mahtani
Consulting or Advisory Role - Agendia; Amgen; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; Gilead Sciences; Hologic/Biotheranostics; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Sermonix Pharmaceuticals; Stemline Therapeutics
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; bioTheranostics; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen